1039 related articles for article (PubMed ID: 26086329)
1. SGLT2 Inhibitors May Predispose to Ketoacidosis.
Taylor SI; Blau JE; Rother KI
J Clin Endocrinol Metab; 2015 Aug; 100(8):2849-52. PubMed ID: 26086329
[TBL] [Abstract][Full Text] [Related]
2. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
Valek R; Von der Mark J
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
[TBL] [Abstract][Full Text] [Related]
3. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
[TBL] [Abstract][Full Text] [Related]
4. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Lindberg MJ; Kristensen FB; Yildiz A
Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
[TBL] [Abstract][Full Text] [Related]
5. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
Qiu H; Novikov A; Vallon V
Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
[TBL] [Abstract][Full Text] [Related]
6. Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Quarella M; Walser D; Brändle M; Fournier JY; Bilz S
J Clin Endocrinol Metab; 2017 May; 102(5):1451-1453. PubMed ID: 28323955
[TBL] [Abstract][Full Text] [Related]
7. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
8. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
10. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin-Associated Diabetic Ketoacidosis.
Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
[No Abstract] [Full Text] [Related]
12. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Donnan K; Segar L
Eur J Pharmacol; 2019 Mar; 846():23-29. PubMed ID: 30639796
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
Wang AY; Hou SK; Li SJ; Kao WF
Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
[No Abstract] [Full Text] [Related]
14. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Rizos EC; Elisaf MS
Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
[TBL] [Abstract][Full Text] [Related]
15. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Vallon V
Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
[TBL] [Abstract][Full Text] [Related]
16. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
Yamamoto M; Ide N; Kitajima S; Obayashi M; Asada K; Matsushima S; Ito M
Yakugaku Zasshi; 2019; 139(11):1479-1483. PubMed ID: 31685745
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors.
Lin YH
J Formos Med Assoc; 2018 Sep; 117(9):849-854. PubMed ID: 29477576
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Leader R; Cowen J; Rajeev SP
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537607
[TBL] [Abstract][Full Text] [Related]
19. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Lupsa BC; Inzucchi SE
Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
[TBL] [Abstract][Full Text] [Related]
20. Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
Park JH; Seo I; Shim HM; Cho H
J Pineal Res; 2020 Mar; 68(2):e12623. PubMed ID: 31743484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
